Multicenter Trial of Prednisone in Alzheimer's Disease
2 other identifiers
interventional
N/A
1 country
19
Brief Summary
This is a randomized placebo controlled, double blind study. Patients who meet eligibility criteria and decide to participate in the study will be randomly assigned to receive either drug treatment or a placebo. Neither the patients nor the participating investigators will know who is receiving the drugs and who is receiving the placebo. Participation involves 15 outpatient clinic visits over a 68 week period. Patients take study medication at varying doses (the maximum dose is 20 mg daily), along with calcium and vitamin supplements.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
19 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 29, 1999
CompletedFirst Posted
Study publicly available on registry
November 1, 1999
CompletedJune 24, 2005
February 1, 2005
October 29, 1999
June 23, 2005
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- Patients with Alzheimer's disease who are in stable medical condition
You may not qualify if:
- Patients with diabetes or severe osteoporosis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (19)
University of Alabama, Birmingham
Birmingham, Alabama, 35294-0017, United States
University of Southern California
Los Angeles, California, 90033, United States
University of California, San Diego
San Diego, California, 92093-0949, United States
Mayo Clinic Jacksonville
Jacksonville, Florida, 32225, United States
University of Miami
Miami, Florida, 33140, United States
University of South Florida
Tampa, Florida, 33162, United States
Indiana University Alzheimer's Center
Indianapolis, Indiana, 46202, United States
University of Kansas Medical Center
Kansas City, Kansas, 66160, United States
Johns Hopkins University
Baltimore, Maryland, 21224, United States
University of Minnesota
Minneapolis, Minnesota, 55455, United States
Washington University
St Louis, Missouri, 63110, United States
New York University Medical Center
New York, New York, 10016, United States
Mount Sinai Medical Center
New York, New York, 10029, United States
Columbia Presbyterian Medical Center
New York, New York, 11032, United States
University of Rochester
Rochester, New York, 14620, United States
Burke Medical Research Institute
White Plains, New York, 10605, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213, United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37212-8646, United States
University of Texas
Dallas, Texas, 75235-9070, United States
Related Publications (1)
Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, Weiner MF, Farlow MR, Sano M, Grundman M, Thal LJ. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology. 2000 Feb 8;54(3):588-93. doi: 10.1212/wnl.54.3.588.
PMID: 10680787RESULT
Related Links
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Leon Thal, MD.
University of California, San Diego
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Sponsor Type
- NIH
Study Record Dates
First Submitted
October 29, 1999
First Posted
November 1, 1999
Last Updated
June 24, 2005
Record last verified: 2005-02